The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Global Gene Therapy On Cardiovascular Disease Market Research Report 2025
Synopsis
Gene therapy is an experimental technique that uses genes to treat or prevent disease. In the future, this technique may allow doctors to treat a disorder by inserting a gene into a patient's cells instead of using drugs or surgery.
Although several conventional small-molecule treatments are available for common cardiovascular problems, gene therapy is a potential treatment option for acquired and inherited cardiovascular diseases that remain with unmet clinical needs.
The global Gene Therapy On Cardiovascular Disease market was valued at US$ 13 million in 2023 and is anticipated to reach US$ 8593.6 million by 2030, witnessing a CAGR of 91.0% during the forecast period 2024-2030.
Global key players of Gene Therapy On Cardiovascular Disease include Biogen, Novartis, Gilead Sciences, Sarepta Therapeutics, Alnylam Pharmaceuticals and Amgen, etc. Top three players occupy for a share about 76%. In terms of product, Non-Viral Gene Therapy is the largest segment, with a share over 100%. In terms of application, Vascular Disease is the largest market, with a share over 100%.
This report aims to provide a comprehensive presentation of the global market for Gene Therapy On Cardiovascular Disease, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Gene Therapy On Cardiovascular Disease.
Report Scope
The Gene Therapy On Cardiovascular Disease market size, estimations, and forecasts are provided in terms of revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Gene Therapy On Cardiovascular Disease market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Gene Therapy On Cardiovascular Disease companies, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Biogen
Novartis
Gilead Sciences
Sarepta Therapeutics
Alnylam Pharmaceuticals
Amgen
Spark Therapeutics
Akcea Therapeutics
bluebird bio
Sunway Biotech
SIBIONO
AnGes
Orchard Therapeutics
Human Stem Cells Institute
Segment by Type
Viral Gene Therapy
Non-Viral Gene Therapy
Segment by Application
Heart Disease
Vascular Disease
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Gene Therapy On Cardiovascular Disease companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
Gene therapy is an experimental technique that uses genes to treat or prevent disease. In the future, this technique may allow doctors to treat a disorder by inserting a gene into a patient's cells instead of using drugs or surgery.
Although several conventional small-molecule treatments are available for common cardiovascular problems, gene therapy is a potential treatment option for acquired and inherited cardiovascular diseases that remain with unmet clinical needs.
The global Gene Therapy On Cardiovascular Disease market was valued at US$ 13 million in 2023 and is anticipated to reach US$ 8593.6 million by 2030, witnessing a CAGR of 91.0% during the forecast period 2024-2030.
Global key players of Gene Therapy On Cardiovascular Disease include Biogen, Novartis, Gilead Sciences, Sarepta Therapeutics, Alnylam Pharmaceuticals and Amgen, etc. Top three players occupy for a share about 76%. In terms of product, Non-Viral Gene Therapy is the largest segment, with a share over 100%. In terms of application, Vascular Disease is the largest market, with a share over 100%.
This report aims to provide a comprehensive presentation of the global market for Gene Therapy On Cardiovascular Disease, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Gene Therapy On Cardiovascular Disease.
Report Scope
The Gene Therapy On Cardiovascular Disease market size, estimations, and forecasts are provided in terms of revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Gene Therapy On Cardiovascular Disease market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Gene Therapy On Cardiovascular Disease companies, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Biogen
Novartis
Gilead Sciences
Sarepta Therapeutics
Alnylam Pharmaceuticals
Amgen
Spark Therapeutics
Akcea Therapeutics
bluebird bio
Sunway Biotech
SIBIONO
AnGes
Orchard Therapeutics
Human Stem Cells Institute
Segment by Type
Viral Gene Therapy
Non-Viral Gene Therapy
Segment by Application
Heart Disease
Vascular Disease
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Gene Therapy On Cardiovascular Disease companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
Index1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Gene Therapy On Cardiovascular Disease Market Size Growth Rate by Type: 2019 VS 2023 VS 2030
1.2.2 Viral Gene Therapy
1.2.3 Non-Viral Gene Therapy
1.3 Market by Application
1.3.1 Global Gene Therapy On Cardiovascular Disease Market Growth by Application: 2019 VS 2023 VS 2030
1.3.2 Heart Disease
1.3.3 Vascular Disease
1.4 Study Objectives
1.5 Years Considered
1.6 Years Considered
2 Global Growth Trends
2.1 Global Gene Therapy On Cardiovascular Disease Market Perspective (2019-2030)
2.2 Gene Therapy On Cardiovascular Disease Growth Trends by Region
2.2.1 Global Gene Therapy On Cardiovascular Disease Market Size by Region: 2019 VS 2023 VS 2030
2.2.2 Gene Therapy On Cardiovascular Disease Historic Market Size by Region (2019-2024)
2.2.3 Gene Therapy On Cardiovascular Disease Forecasted Market Size by Region (2025-2030)
2.3 Gene Therapy On Cardiovascular Disease Market Dynamics
2.3.1 Gene Therapy On Cardiovascular Disease Industry Trends
2.3.2 Gene Therapy On Cardiovascular Disease Market Drivers
2.3.3 Gene Therapy On Cardiovascular Disease Market Challenges
2.3.4 Gene Therapy On Cardiovascular Disease Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Gene Therapy On Cardiovascular Disease Players by Revenue
3.1.1 Global Top Gene Therapy On Cardiovascular Disease Players by Revenue (2019-2024)
3.1.2 Global Gene Therapy On Cardiovascular Disease Revenue Market Share by Players (2019-2024)
3.2 Global Gene Therapy On Cardiovascular Disease Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Gene Therapy On Cardiovascular Disease Revenue
3.4 Global Gene Therapy On Cardiovascular Disease Market Concentration Ratio
3.4.1 Global Gene Therapy On Cardiovascular Disease Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Gene Therapy On Cardiovascular Disease Revenue in 2023
3.5 Gene Therapy On Cardiovascular Disease Key Players Head office and Area Served
3.6 Key Players Gene Therapy On Cardiovascular Disease Product Solution and Service
3.7 Date of Enter into Gene Therapy On Cardiovascular Disease Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Gene Therapy On Cardiovascular Disease Breakdown Data by Type
4.1 Global Gene Therapy On Cardiovascular Disease Historic Market Size by Type (2019-2024)
4.2 Global Gene Therapy On Cardiovascular Disease Forecasted Market Size by Type (2025-2030)
5 Gene Therapy On Cardiovascular Disease Breakdown Data by Application
5.1 Global Gene Therapy On Cardiovascular Disease Historic Market Size by Application (2019-2024)
5.2 Global Gene Therapy On Cardiovascular Disease Forecasted Market Size by Application (2025-2030)
6 North America
6.1 North America Gene Therapy On Cardiovascular Disease Market Size (2019-2030)
6.2 North America Gene Therapy On Cardiovascular Disease Market Growth Rate by Country: 2019 VS 2023 VS 2030
6.3 North America Gene Therapy On Cardiovascular Disease Market Size by Country (2019-2024)
6.4 North America Gene Therapy On Cardiovascular Disease Market Size by Country (2025-2030)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Gene Therapy On Cardiovascular Disease Market Size (2019-2030)
7.2 Europe Gene Therapy On Cardiovascular Disease Market Growth Rate by Country: 2019 VS 2023 VS 2030
7.3 Europe Gene Therapy On Cardiovascular Disease Market Size by Country (2019-2024)
7.4 Europe Gene Therapy On Cardiovascular Disease Market Size by Country (2025-2030)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Gene Therapy On Cardiovascular Disease Market Size (2019-2030)
8.2 Asia-Pacific Gene Therapy On Cardiovascular Disease Market Growth Rate by Region: 2019 VS 2023 VS 2030
8.3 Asia-Pacific Gene Therapy On Cardiovascular Disease Market Size by Region (2019-2024)
8.4 Asia-Pacific Gene Therapy On Cardiovascular Disease Market Size by Region (2025-2030)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Gene Therapy On Cardiovascular Disease Market Size (2019-2030)
9.2 Latin America Gene Therapy On Cardiovascular Disease Market Growth Rate by Country: 2019 VS 2023 VS 2030
9.3 Latin America Gene Therapy On Cardiovascular Disease Market Size by Country (2019-2024)
9.4 Latin America Gene Therapy On Cardiovascular Disease Market Size by Country (2025-2030)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Gene Therapy On Cardiovascular Disease Market Size (2019-2030)
10.2 Middle East & Africa Gene Therapy On Cardiovascular Disease Market Growth Rate by Country: 2019 VS 2023 VS 2030
10.3 Middle East & Africa Gene Therapy On Cardiovascular Disease Market Size by Country (2019-2024)
10.4 Middle East & Africa Gene Therapy On Cardiovascular Disease Market Size by Country (2025-2030)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Biogen
11.1.1 Biogen Company Detail
11.1.2 Biogen Business Overview
11.1.3 Biogen Gene Therapy On Cardiovascular Disease Introduction
11.1.4 Biogen Revenue in Gene Therapy On Cardiovascular Disease Business (2019-2024)
11.1.5 Biogen Recent Development
11.2 Novartis
11.2.1 Novartis Company Detail
11.2.2 Novartis Business Overview
11.2.3 Novartis Gene Therapy On Cardiovascular Disease Introduction
11.2.4 Novartis Revenue in Gene Therapy On Cardiovascular Disease Business (2019-2024)
11.2.5 Novartis Recent Development
11.3 Gilead Sciences
11.3.1 Gilead Sciences Company Detail
11.3.2 Gilead Sciences Business Overview
11.3.3 Gilead Sciences Gene Therapy On Cardiovascular Disease Introduction
11.3.4 Gilead Sciences Revenue in Gene Therapy On Cardiovascular Disease Business (2019-2024)
11.3.5 Gilead Sciences Recent Development
11.4 Sarepta Therapeutics
11.4.1 Sarepta Therapeutics Company Detail
11.4.2 Sarepta Therapeutics Business Overview
11.4.3 Sarepta Therapeutics Gene Therapy On Cardiovascular Disease Introduction
11.4.4 Sarepta Therapeutics Revenue in Gene Therapy On Cardiovascular Disease Business (2019-2024)
11.4.5 Sarepta Therapeutics Recent Development
11.5 Alnylam Pharmaceuticals
11.5.1 Alnylam Pharmaceuticals Company Detail
11.5.2 Alnylam Pharmaceuticals Business Overview
11.5.3 Alnylam Pharmaceuticals Gene Therapy On Cardiovascular Disease Introduction
11.5.4 Alnylam Pharmaceuticals Revenue in Gene Therapy On Cardiovascular Disease Business (2019-2024)
11.5.5 Alnylam Pharmaceuticals Recent Development
11.6 Amgen
11.6.1 Amgen Company Detail
11.6.2 Amgen Business Overview
11.6.3 Amgen Gene Therapy On Cardiovascular Disease Introduction
11.6.4 Amgen Revenue in Gene Therapy On Cardiovascular Disease Business (2019-2024)
11.6.5 Amgen Recent Development
11.7 Spark Therapeutics
11.7.1 Spark Therapeutics Company Detail
11.7.2 Spark Therapeutics Business Overview
11.7.3 Spark Therapeutics Gene Therapy On Cardiovascular Disease Introduction
11.7.4 Spark Therapeutics Revenue in Gene Therapy On Cardiovascular Disease Business (2019-2024)
11.7.5 Spark Therapeutics Recent Development
11.8 Akcea Therapeutics
11.8.1 Akcea Therapeutics Company Detail
11.8.2 Akcea Therapeutics Business Overview
11.8.3 Akcea Therapeutics Gene Therapy On Cardiovascular Disease Introduction
11.8.4 Akcea Therapeutics Revenue in Gene Therapy On Cardiovascular Disease Business (2019-2024)
11.8.5 Akcea Therapeutics Recent Development
11.9 bluebird bio
11.9.1 bluebird bio Company Detail
11.9.2 bluebird bio Business Overview
11.9.3 bluebird bio Gene Therapy On Cardiovascular Disease Introduction
11.9.4 bluebird bio Revenue in Gene Therapy On Cardiovascular Disease Business (2019-2024)
11.9.5 bluebird bio Recent Development
11.10 Sunway Biotech
11.10.1 Sunway Biotech Company Detail
11.10.2 Sunway Biotech Business Overview
11.10.3 Sunway Biotech Gene Therapy On Cardiovascular Disease Introduction
11.10.4 Sunway Biotech Revenue in Gene Therapy On Cardiovascular Disease Business (2019-2024)
11.10.5 Sunway Biotech Recent Development
11.11 SIBIONO
11.11.1 SIBIONO Company Detail
11.11.2 SIBIONO Business Overview
11.11.3 SIBIONO Gene Therapy On Cardiovascular Disease Introduction
11.11.4 SIBIONO Revenue in Gene Therapy On Cardiovascular Disease Business (2019-2024)
11.11.5 SIBIONO Recent Development
11.12 AnGes
11.12.1 AnGes Company Detail
11.12.2 AnGes Business Overview
11.12.3 AnGes Gene Therapy On Cardiovascular Disease Introduction
11.12.4 AnGes Revenue in Gene Therapy On Cardiovascular Disease Business (2019-2024)
11.12.5 AnGes Recent Development
11.13 Orchard Therapeutics
11.13.1 Orchard Therapeutics Company Detail
11.13.2 Orchard Therapeutics Business Overview
11.13.3 Orchard Therapeutics Gene Therapy On Cardiovascular Disease Introduction
11.13.4 Orchard Therapeutics Revenue in Gene Therapy On Cardiovascular Disease Business (2019-2024)
11.13.5 Orchard Therapeutics Recent Development
11.14 Human Stem Cells Institute
11.14.1 Human Stem Cells Institute Company Detail
11.14.2 Human Stem Cells Institute Business Overview
11.14.3 Human Stem Cells Institute Gene Therapy On Cardiovascular Disease Introduction
11.14.4 Human Stem Cells Institute Revenue in Gene Therapy On Cardiovascular Disease Business (2019-2024)
11.14.5 Human Stem Cells Institute Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details
List of TablesList of Tables
Table 1. Global Gene Therapy On Cardiovascular Disease Market Size Growth Rate by Type (US$ Million): 2019 VS 2023 VS 2030
Table 2. Key Players of Viral Gene Therapy
Table 3. Key Players of Non-Viral Gene Therapy
Table 4. Global Gene Therapy On Cardiovascular Disease Market Size Growth by Application (US$ Million): 2019 VS 2023 VS 2030
Table 5. Global Gene Therapy On Cardiovascular Disease Market Size by Region (US$ Million): 2019 VS 2023 VS 2030
Table 6. Global Gene Therapy On Cardiovascular Disease Market Size by Region (2019-2024) & (US$ Million)
Table 7. Global Gene Therapy On Cardiovascular Disease Market Share by Region (2019-2024)
Table 8. Global Gene Therapy On Cardiovascular Disease Forecasted Market Size by Region (2025-2030) & (US$ Million)
Table 9. Global Gene Therapy On Cardiovascular Disease Market Share by Region (2025-2030)
Table 10. Gene Therapy On Cardiovascular Disease Market Trends
Table 11. Gene Therapy On Cardiovascular Disease Market Drivers
Table 12. Gene Therapy On Cardiovascular Disease Market Challenges
Table 13. Gene Therapy On Cardiovascular Disease Market Restraints
Table 14. Global Gene Therapy On Cardiovascular Disease Revenue by Players (2019-2024) & (US$ Million)
Table 15. Global Gene Therapy On Cardiovascular Disease Market Share by Players (2019-2024)
Table 16. Global Top Gene Therapy On Cardiovascular Disease Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Gene Therapy On Cardiovascular Disease as of 2023)
Table 17. Ranking of Global Top Gene Therapy On Cardiovascular Disease Companies by Revenue (US$ Million) in 2023
Table 18. Global 5 Largest Players Market Share by Gene Therapy On Cardiovascular Disease Revenue (CR5 and HHI) & (2019-2024)
Table 19. Key Players Headquarters and Area Served
Table 20. Key Players Gene Therapy On Cardiovascular Disease Product Solution and Service
Table 21. Date of Enter into Gene Therapy On Cardiovascular Disease Market
Table 22. Mergers & Acquisitions, Expansion Plans
Table 23. Global Gene Therapy On Cardiovascular Disease Market Size by Type (2019-2024) & (US$ Million)
Table 24. Global Gene Therapy On Cardiovascular Disease Revenue Market Share by Type (2019-2024)
Table 25. Global Gene Therapy On Cardiovascular Disease Forecasted Market Size by Type (2025-2030) & (US$ Million)
Table 26. Global Gene Therapy On Cardiovascular Disease Revenue Market Share by Type (2025-2030)
Table 27. Global Gene Therapy On Cardiovascular Disease Market Size by Application (2019-2024) & (US$ Million)
Table 28. Global Gene Therapy On Cardiovascular Disease Revenue Market Share by Application (2019-2024)
Table 29. Global Gene Therapy On Cardiovascular Disease Forecasted Market Size by Application (2025-2030) & (US$ Million)
Table 30. Global Gene Therapy On Cardiovascular Disease Revenue Market Share by Application (2025-2030)
Table 31. North America Gene Therapy On Cardiovascular Disease Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030
Table 32. North America Gene Therapy On Cardiovascular Disease Market Size by Country (2019-2024) & (US$ Million)
Table 33. North America Gene Therapy On Cardiovascular Disease Market Size by Country (2025-2030) & (US$ Million)
Table 34. Europe Gene Therapy On Cardiovascular Disease Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030
Table 35. Europe Gene Therapy On Cardiovascular Disease Market Size by Country (2019-2024) & (US$ Million)
Table 36. Europe Gene Therapy On Cardiovascular Disease Market Size by Country (2025-2030) & (US$ Million)
Table 37. Asia-Pacific Gene Therapy On Cardiovascular Disease Market Size Growth Rate by Region (US$ Million): 2019 VS 2023 VS 2030
Table 38. Asia-Pacific Gene Therapy On Cardiovascular Disease Market Size by Region (2019-2024) & (US$ Million)
Table 39. Asia-Pacific Gene Therapy On Cardiovascular Disease Market Size by Region (2025-2030) & (US$ Million)
Table 40. Latin America Gene Therapy On Cardiovascular Disease Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030
Table 41. Latin America Gene Therapy On Cardiovascular Disease Market Size by Country (2019-2024) & (US$ Million)
Table 42. Latin America Gene Therapy On Cardiovascular Disease Market Size by Country (2025-2030) & (US$ Million)
Table 43. Middle East & Africa Gene Therapy On Cardiovascular Disease Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030
Table 44. Middle East & Africa Gene Therapy On Cardiovascular Disease Market Size by Country (2019-2024) & (US$ Million)
Table 45. Middle East & Africa Gene Therapy On Cardiovascular Disease Market Size by Country (2025-2030) & (US$ Million)
Table 46. Biogen Company Detail
Table 47. Biogen Business Overview
Table 48. Biogen Gene Therapy On Cardiovascular Disease Product
Table 49. Biogen Revenue in Gene Therapy On Cardiovascular Disease Business (2019-2024) & (US$ Million)
Table 50. Biogen Recent Development
Table 51. Novartis Company Detail
Table 52. Novartis Business Overview
Table 53. Novartis Gene Therapy On Cardiovascular Disease Product
Table 54. Novartis Revenue in Gene Therapy On Cardiovascular Disease Business (2019-2024) & (US$ Million)
Table 55. Novartis Recent Development
Table 56. Gilead Sciences Company Detail
Table 57. Gilead Sciences Business Overview
Table 58. Gilead Sciences Gene Therapy On Cardiovascular Disease Product
Table 59. Gilead Sciences Revenue in Gene Therapy On Cardiovascular Disease Business (2019-2024) & (US$ Million)
Table 60. Gilead Sciences Recent Development
Table 61. Sarepta Therapeutics Company Detail
Table 62. Sarepta Therapeutics Business Overview
Table 63. Sarepta Therapeutics Gene Therapy On Cardiovascular Disease Product
Table 64. Sarepta Therapeutics Revenue in Gene Therapy On Cardiovascular Disease Business (2019-2024) & (US$ Million)
Table 65. Sarepta Therapeutics Recent Development
Table 66. Alnylam Pharmaceuticals Company Detail
Table 67. Alnylam Pharmaceuticals Business Overview
Table 68. Alnylam Pharmaceuticals Gene Therapy On Cardiovascular Disease Product
Table 69. Alnylam Pharmaceuticals Revenue in Gene Therapy On Cardiovascular Disease Business (2019-2024) & (US$ Million)
Table 70. Alnylam Pharmaceuticals Recent Development
Table 71. Amgen Company Detail
Table 72. Amgen Business Overview
Table 73. Amgen Gene Therapy On Cardiovascular Disease Product
Table 74. Amgen Revenue in Gene Therapy On Cardiovascular Disease Business (2019-2024) & (US$ Million)
Table 75. Amgen Recent Development
Table 76. Spark Therapeutics Company Detail
Table 77. Spark Therapeutics Business Overview
Table 78. Spark Therapeutics Gene Therapy On Cardiovascular Disease Product
Table 79. Spark Therapeutics Revenue in Gene Therapy On Cardiovascular Disease Business (2019-2024) & (US$ Million)
Table 80. Spark Therapeutics Recent Development
Table 81. Akcea Therapeutics Company Detail
Table 82. Akcea Therapeutics Business Overview
Table 83. Akcea Therapeutics Gene Therapy On Cardiovascular Disease Product
Table 84. Akcea Therapeutics Revenue in Gene Therapy On Cardiovascular Disease Business (2019-2024) & (US$ Million)
Table 85. Akcea Therapeutics Recent Development
Table 86. bluebird bio Company Detail
Table 87. bluebird bio Business Overview
Table 88. bluebird bio Gene Therapy On Cardiovascular Disease Product
Table 89. bluebird bio Revenue in Gene Therapy On Cardiovascular Disease Business (2019-2024) & (US$ Million)
Table 90. bluebird bio Recent Development
Table 91. Sunway Biotech Company Detail
Table 92. Sunway Biotech Business Overview
Table 93. Sunway Biotech Gene Therapy On Cardiovascular Disease Product
Table 94. Sunway Biotech Revenue in Gene Therapy On Cardiovascular Disease Business (2019-2024) & (US$ Million)
Table 95. Sunway Biotech Recent Development
Table 96. SIBIONO Company Detail
Table 97. SIBIONO Business Overview
Table 98. SIBIONO Gene Therapy On Cardiovascular Disease Product
Table 99. SIBIONO Revenue in Gene Therapy On Cardiovascular Disease Business (2019-2024) & (US$ Million)
Table 100. SIBIONO Recent Development
Table 101. AnGes Company Detail
Table 102. AnGes Business Overview
Table 103. AnGes Gene Therapy On Cardiovascular Disease Product
Table 104. AnGes Revenue in Gene Therapy On Cardiovascular Disease Business (2019-2024) & (US$ Million)
Table 105. AnGes Recent Development
Table 106. Orchard Therapeutics Company Detail
Table 107. Orchard Therapeutics Business Overview
Table 108. Orchard Therapeutics Gene Therapy On Cardiovascular Disease Product
Table 109. Orchard Therapeutics Revenue in Gene Therapy On Cardiovascular Disease Business (2019-2024) & (US$ Million)
Table 110. Orchard Therapeutics Recent Development
Table 111. Human Stem Cells Institute Company Detail
Table 112. Human Stem Cells Institute Business Overview
Table 113. Human Stem Cells Institute Gene Therapy On Cardiovascular Disease Product
Table 114. Human Stem Cells Institute Revenue in Gene Therapy On Cardiovascular Disease Business (2019-2024) & (US$ Million)
Table 115. Human Stem Cells Institute Recent Development
Table 116. Research Programs/Design for This Report
Table 117. Key Data Information from Secondary Sources
Table 118. Key Data Information from Primary Sources
List of Figures
Figure 1. Global Gene Therapy On Cardiovascular Disease Market Size Comparison by Type (2024-2030) & (US$ Million)
Figure 2. Global Gene Therapy On Cardiovascular Disease Market Share by Type: 2023 VS 2030
Figure 3. Viral Gene Therapy Features
Figure 4. Non-Viral Gene Therapy Features
Figure 5. Global Gene Therapy On Cardiovascular Disease Market Size Comparison by Application (2024-2030) & (US$ Million)
Figure 6. Global Gene Therapy On Cardiovascular Disease Market Share by Application: 2023 VS 2030
Figure 7. Heart Disease Case Studies
Figure 8. Vascular Disease Case Studies
Figure 9. Gene Therapy On Cardiovascular Disease Report Years Considered
Figure 10. Global Gene Therapy On Cardiovascular Disease Market Size (US$ Million), Year-over-Year: 2019-2030
Figure 11. Global Gene Therapy On Cardiovascular Disease Market Size, (US$ Million), 2019 VS 2023 VS 2030
Figure 12. Global Gene Therapy On Cardiovascular Disease Market Share by Region: 2023 VS 2030
Figure 13. Global Gene Therapy On Cardiovascular Disease Market Share by Players in 2023
Figure 14. Global Top Gene Therapy On Cardiovascular Disease Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Gene Therapy On Cardiovascular Disease as of 2023)
Figure 15. The Top 10 and 5 Players Market Share by Gene Therapy On Cardiovascular Disease Revenue in 2023
Figure 16. North America Gene Therapy On Cardiovascular Disease Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 17. North America Gene Therapy On Cardiovascular Disease Market Share by Country (2019-2030)
Figure 18. United States Gene Therapy On Cardiovascular Disease Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 19. Canada Gene Therapy On Cardiovascular Disease Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 20. Europe Gene Therapy On Cardiovascular Disease Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 21. Europe Gene Therapy On Cardiovascular Disease Market Share by Country (2019-2030)
Figure 22. Germany Gene Therapy On Cardiovascular Disease Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 23. France Gene Therapy On Cardiovascular Disease Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 24. U.K. Gene Therapy On Cardiovascular Disease Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 25. Italy Gene Therapy On Cardiovascular Disease Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 26. Russia Gene Therapy On Cardiovascular Disease Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 27. Nordic Countries Gene Therapy On Cardiovascular Disease Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 28. Asia-Pacific Gene Therapy On Cardiovascular Disease Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 29. Asia-Pacific Gene Therapy On Cardiovascular Disease Market Share by Region (2019-2030)
Figure 30. China Gene Therapy On Cardiovascular Disease Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 31. Japan Gene Therapy On Cardiovascular Disease Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 32. South Korea Gene Therapy On Cardiovascular Disease Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 33. Southeast Asia Gene Therapy On Cardiovascular Disease Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 34. India Gene Therapy On Cardiovascular Disease Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 35. Australia Gene Therapy On Cardiovascular Disease Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 36. Latin America Gene Therapy On Cardiovascular Disease Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 37. Latin America Gene Therapy On Cardiovascular Disease Market Share by Country (2019-2030)
Figure 38. Mexico Gene Therapy On Cardiovascular Disease Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 39. Brazil Gene Therapy On Cardiovascular Disease Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 40. Middle East & Africa Gene Therapy On Cardiovascular Disease Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 41. Middle East & Africa Gene Therapy On Cardiovascular Disease Market Share by Country (2019-2030)
Figure 42. Turkey Gene Therapy On Cardiovascular Disease Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 43. Saudi Arabia Gene Therapy On Cardiovascular Disease Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 44. Biogen Revenue Growth Rate in Gene Therapy On Cardiovascular Disease Business (2019-2024)
Figure 45. Novartis Revenue Growth Rate in Gene Therapy On Cardiovascular Disease Business (2019-2024)
Figure 46. Gilead Sciences Revenue Growth Rate in Gene Therapy On Cardiovascular Disease Business (2019-2024)
Figure 47. Sarepta Therapeutics Revenue Growth Rate in Gene Therapy On Cardiovascular Disease Business (2019-2024)
Figure 48. Alnylam Pharmaceuticals Revenue Growth Rate in Gene Therapy On Cardiovascular Disease Business (2019-2024)
Figure 49. Amgen Revenue Growth Rate in Gene Therapy On Cardiovascular Disease Business (2019-2024)
Figure 50. Spark Therapeutics Revenue Growth Rate in Gene Therapy On Cardiovascular Disease Business (2019-2024)
Figure 51. Akcea Therapeutics Revenue Growth Rate in Gene Therapy On Cardiovascular Disease Business (2019-2024)
Figure 52. bluebird bio Revenue Growth Rate in Gene Therapy On Cardiovascular Disease Business (2019-2024)
Figure 53. Sunway Biotech Revenue Growth Rate in Gene Therapy On Cardiovascular Disease Business (2019-2024)
Figure 54. SIBIONO Revenue Growth Rate in Gene Therapy On Cardiovascular Disease Business (2019-2024)
Figure 55. AnGes Revenue Growth Rate in Gene Therapy On Cardiovascular Disease Business (2019-2024)
Figure 56. Orchard Therapeutics Revenue Growth Rate in Gene Therapy On Cardiovascular Disease Business (2019-2024)
Figure 57. Human Stem Cells Institute Revenue Growth Rate in Gene Therapy On Cardiovascular Disease Business (2019-2024)
Figure 58. Bottom-up and Top-down Approaches for This Report
Figure 59. Data Triangulation
Figure 60. Key Executives Interviewed
Published By : QY Research
Why ‘The Market Reports’
In Business:
Pre Sales Support:
Post Sales Support:
Turn Around Time:
Clients Served:
Clients Assisted:
Client Types:
Payment:
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
